MTOR and cancer: However, compared with treated cancer cells, p-PI3K levels were significantly lower in normal cell lines, while p-AKT and p-mTOR were essentially absent, suggesting that the PI3K pathway is less active in normal cells than in cancer cells, revealing that Parishin A treatment leads to a decrease in the phosphorylation levels of PI3K, AKT, and mTOR, whereas the total levels of these proteins remain unchanged.